Vivanza Biosciences Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 515837, "name": "Vivanza Biosci.", "stock_name": "Vivanza Biosci.", "full_name": "Vivanza Biosciences Ltd", "name_url": "stocks-analysis/vivanza-biosci", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "2.07", "chg": 0.09, "chgp": "4.55%", "dir": 1, "prev_price": "1.98", "mcapval": "8.00 Cr", "mcap": "Micro Cap", "scripcode": 530057, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 67, "indexname": "India SENSEX", "isin": "INE984E01035", "curr_date": "Apr 30", "curr_time": "", "bse_nse_vol": "13.89 k", "exc_status": "Active", "traded_date": "Apr 30, 2026", "traded_date_str": "2026 04 30", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vivanza-biosci-515837-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3969338", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VivanzaBioscien_valuationdot_3969338.png", "date": "2026-04-30 08:00:22", "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite ongoing challenges reflected in its negative returns and profitability metrics, the stock’s current price-to-earnings and price-to-book value ratios suggest a more compelling entry point compared to peers and historical averages." }, { "title": "When is the next results date for Vivanza Biosciences Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-vivanza-biosciences-ltd-3969194", "imagepath": "", "date": "2026-04-29 23:16:25", "description": "The next results date for Vivanza Biosciences Ltd is scheduled for 04 May 2026...." }, { "title": "Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3956641", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VivanzaBioscien_valuationdot_3956641.png", "date": "2026-04-22 08:00:51", "description": "Vivanza Biosciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade, despite ongoing challenges in profitability and returns. This change, driven primarily by a sharp correction in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks." }, { "title": "Vivanza Biosciences Gains 14.84%: 2 Key Factors Driving the Weekly Surge", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-gains-1484-2-key-factors-driving-the-weekly-surge-3943078", "imagepath": "", "date": "2026-04-11 17:04:52", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>6 Apr:</strong> Week opens at ₹1.82</p>\n <p><strong>7 Apr:</strong> Valuation shifts highlight renewed price attractiveness</p>\n <p><strong>8 Apr:</strong> MarketsMOJO upgrades rating from Strong Sell to Sell</p>\n <p><strong>10 Apr:</strong> Week closes at ₹2.09, +14.84% weekly gain</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1.82</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.2.09</div><div class=\"stat-change positive\">..." }, { "title": "Vivanza Biosciences Ltd Upgraded to Sell on Technical and Valuation Improvements", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-ltd-upgraded-to-sell-on-technical-and-valuation-improvements-3936571", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VivanzaBioscien_mojoScore_3936571.png", "date": "2026-04-08 08:12:39", "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026. This change reflects a nuanced improvement across technical indicators and valuation metrics, despite ongoing challenges in financial trends and quality parameters. The stock’s recent price movement and underlying fundamentals have been carefully analysed to understand the rationale behind this shift." }, { "title": "Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Market Challenges", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-market-challenges-3934991", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VivanzaBioscien_valuationdot_3934991.png", "date": "2026-04-07 08:00:33", "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from fair to attractive territory. Despite a challenging operational backdrop reflected in negative returns and profitability metrics, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of market expectations. This article analyses the recent valuation changes, compares Vivanza’s metrics with peers and historical benchmarks, and assesses the implications for investors." }, { "title": "Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.75 as Sell-Off Deepens", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-stock-hits-52-week-low-amidst-continued-downtrend-3925090", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VivanzaBioscien_priceRelatedfactors_3925090.png", "date": "2026-03-30 13:38:48", "description": "For the second consecutive session, Vivanza Biosciences Ltd has seen its share price decline further, hitting a fresh 52-week low of Rs 1.75 on 30 Mar 2026. This drop extends the stock’s downward trend, which has now resulted in a 5.41% loss over the last two days, underperforming its sector and broader market indices." }, { "title": "Vivanza Biosciences Declines 5.76%: 3 Key Factors Behind the Weekly Slide", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-declines-576-3-key-factors-behind-the-weekly-slide-3922069", "imagepath": "", "date": "2026-03-28 15:08:59", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>23 Mar:</strong> Stock hits 52-week low at Rs.1.82 amid market downturn</p>\n <p><strong>24 Mar:</strong> Valuation shifts to fair grade with Strong Sell mojo rating</p>\n <p><strong>27 Mar:</strong> New 52-week low recorded at Rs.1.81</p>\n <p><strong>Weekly Close:</strong> Rs.1.80, down 5.76% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1.91</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1.80</div><div class=\"..." }, { "title": "Why is Vivanza Biosciences Ltd falling/rising?", "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vivanza-biosciences-ltd-fallingrising-3921096", "imagepath": "", "date": "2026-03-28 01:26:18", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Vivanza Biosciences Ltd’s share price has been on a downward trajectory over multiple time frames. In the past week, the stock has declined by 5.76%, significantly underperforming the Sensex, which fell by only 1.27% during the same period. The one-month performance further emphasises this trend, with Vivanza’s shares dropping 11.76%, compared to the Sensex’s 9.48% fall. Year-to-date, the stock has lost 18.18%, outpacing the broader market’s decline of 13.66%. Over the last year, the stock has fallen 11.33%, while the Sensex gained 5.18%, highlighting a persistent weakness in the company’s equity relative to the benchmark.</p>\n<p>Longer-term data paints a more concerning picture. Over five years, Vivanza Biosciences has plummeted by 86..." } ], "total": 185, "sid": "515837", "stock_news_url": "https://www.marketsmojo.com/news/vivanza-biosciences-515837" }, "announcements": [ { "caption": "Board Meeting Intimation for Board Meeting Intimation For Intimation Under Regulation 29(1)(A) And Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015", "datetime": "28-Apr-2026", "details": "Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2026 inter alia to consider and approve Vivanza Biosciences Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2026 inter alia to consider and approve 1. Audited Standalone and Consolidated Results along with Audit Report for the Quarter and Year ended 31st March 2026; 2. Any other business with the permission of Chairman.", "source": "BSE" }, { "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance", "datetime": "15-Apr-2026", "details": "Non-Applicability of Regulation 24A of SEBI(LODR) Regulations 2015", "source": "BSE" }, { "caption": "Non-Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.", "datetime": "14-Apr-2026", "details": "Pursuant to Regulation 32 of SEBI (LODR) Regulations 2015 attaching herewith Non-Applicability of Statement of Deviation.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "", "data": [ { "title": "BOARD MEETING", "txt": "04 May 2026" } ] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Vivanza Biosciences Ltd has announced <strong>1:10</strong> stock split, ex-date: 24 Mar 23", "dt": "2023-03-24", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

6 Apr: Week opens at ₹1.82

7 Apr: Valuation shifts highlight renewed price attractiveness

8 Apr: MarketsMOJO upgrades rating from Strong Sell to Sell

10 Apr: Week closes at ₹2.09, +14.84% weekly gain

Read full news article

Vivanza Biosciences Ltd Upgraded to Sell on Technical and Valuation Improvements

2026-04-08 08:12:39

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026. This change reflects a nuanced improvement across technical indicators and valuation metrics, despite ongoing challenges in financial trends and quality parameters. The stock’s recent price movement and underlying fundamentals have been carefully analysed to understand the rationale behind this shift.

Read full news article

Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Market Challenges

2026-04-07 08:00:33

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from fair to attractive territory. Despite a challenging operational backdrop reflected in negative returns and profitability metrics, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of market expectations. This article analyses the recent valuation changes, compares Vivanza’s metrics with peers and historical benchmarks, and assesses the implications for investors.

Read full news article

Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.75 as Sell-Off Deepens

2026-03-30 13:38:48

For the second consecutive session, Vivanza Biosciences Ltd has seen its share price decline further, hitting a fresh 52-week low of Rs 1.75 on 30 Mar 2026. This drop extends the stock’s downward trend, which has now resulted in a 5.41% loss over the last two days, underperforming its sector and broader market indices.

Read full news article

Vivanza Biosciences Declines 5.76%: 3 Key Factors Behind the Weekly Slide

2026-03-28 15:08:59

Key Events This Week

23 Mar: Stock hits 52-week low at Rs.1.82 amid market downturn

24 Mar: Valuation shifts to fair grade with Strong Sell mojo rating

27 Mar: New 52-week low recorded at Rs.1.81

Weekly Close: Rs.1.80, down 5.76% for the week

Read full news article

Why is Vivanza Biosciences Ltd falling/rising?

2026-03-28 01:26:18

Recent Price Movement and Market Context

Vivanza Biosciences Ltd’s share price has been on a downward trajectory over multiple time frames. In the past week, the stock has declined by 5.76%, significantly underperforming the Sensex, which fell by only 1.27% during the same period. The one-month performance further emphasises this trend, with Vivanza’s shares dropping 11.76%, compared to the Sensex’s 9.48% fall. Year-to-date, the stock has lost 18.18%, outpacing the broader market’s decline of 13.66%. Over the last year, the stock has fallen 11.33%, while the Sensex gained 5.18%, highlighting a persistent weakness in the company’s equity relative to the benchmark.

Longer-term data paints a more concerning picture. Over five years, Vivanza Biosciences has plummeted by 86...

Read full news article

View All News